VeraSci attended CNS Summit in Boca Raton, Florida, November 1-4, 2018. CNS Summit is a platform for change in a community passionate about shaping the future through collaboration, innovation, and technology.
This year’s conference proved to be a dynamic environment for networking, sharing ideas, and exploring the future of drug development. The event included stimulating keynote sessions, engaging panel discussions, educational breakouts, and facilitated motivational collaboration with like-minded individuals.
VeraSci engaged with several innovative companies to explore novel digital endpoints, and sponsors and CRO partners were able to interact with the latest VeraSci Pathway® assessments at our newly rebranded booth.
Luca Pani, VeraSci’s VP of Regulatory Strategy and Market Access Innovation, interviewed FDA Associate Director of Digital Health Bakul Patel as well as participated in a rousing panel discussion regarding commercializing innovation.
VeraSci also presented their latest findings using the Pathway BAC. Their presentation “Predictive value and test-retest reliability of the tablet-based Brief Assessment of Cognition (BAC App) for assessment of cognition in aging” detailed results from our brief tablet-based assessment of the paper-and-pencil based Brief Assessment of Cognition (BAC) assessing multiple cognitive domains, including verbal memory, working memory, motor function, verbal fluency, processing speed and executive function. Our presentation demonstrated the validity of the BAC in older individuals with subjective cognitive decline, showing the diagnostic sensitivity, specificity and test-retest reliability of the BAC, and paving the way for the use of the BAC as a screening tool for studies of cognitive aging and Mild Cognitive Impairment.